Oncology

A new study estimates that it would cost Medicare about $2 billion a year to screen certain current and former heavy smokers for lung cancer.

NICE rejected Celgene's Revlimid again for treating patients with myelodysplastic syndrome, quoting concerns with cost-effectiveness of the drug.

CO-1686 was assigned breakthrough designation by the FDA as monotherapy for the treatment of EGFR-mutant NSCLC patients.

Results presented at the 2014 American Urological Association (AUA) meeting in Florida revealed that Myriad's prostate cancer diagnostic test could predict mortality risk in prostate cancer.

In the new issue of Evidence-Based Oncology, Ellen T. Matloff, MS, CGC, and Rachel E. Barnett, MS, CGC, of the Yale Cancer Center and Robert Nussbaum, MD, of UC San Francisco write that efforts by some genetic testing laboratories to grab market share in the lucrative BRCA testing market may put patients at risk, while violating ethical standards issued by the American Medical Association.

Combining a novel radioimmunotherapy treatment with gemcitabine presented encouraging results in PDAC patients who had undergone metastasis. The data was presented at a AACR special conference currently being held in New Orleans.

GSK/GenMab's monoclonal antibody, Azerra, failed to improve PFS over a rituxan/chemotherapy combination in patients with relapsed/refractory diffuse large B-cell lymphoma.

Researchers at Brown University may provide a new early diagnostic test for pancreatic cancer.

Encouraging results from mid-trial analysis have prompted an early halt of the clinical trial for palbociclib and plans to apply for approval.

Orteronel combined with prednisone showed significant PFS but not OS in a double-blind, randomized phase 3 trial.

A leading Belgium-based company that offers personalized medicine to cancer patients, OncoDNA, has chosen to partner with N-of-One for interpretation of next-generation sequencing data of tumor samples.

BMS announced in a press release the breakthrough designation received by it's PD-1 inhibitor antibody, nivolumab, for treating Hodgkin's lymphoma.

LETTER TO THE EDITOR.

Stage IV NSCLC patients with metastatic SCC showed significantly improved survival when necitumumab, an EGFR-targeted antibody, was combined with gemcitabine and cisplatin (11.5 months), compared to chemotherapy alone (9.9 months).

Every person covered by Medicare would shell out an additional $3 a month if the government agreed to pay to screen certain current and former smokers for lung cancer, a new study estimates.

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN Guidelines Updates

NCCN guidelines Updates

NCCN Guidelines Updates